{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009273","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.339674+00:00","generated_at":"2026-05-22T02:58:23.404000+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M","bullets":["Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.","Thyroid revenue $8.0M (+19% YoY) to record; test volume up 16%.","Cash collections $11.3M (+10% YoY) to record; adjusted EBITDA $2.1M vs $1.2M.","Initiates FY2025 revenue guidance of approx. $38M despite PancraGEN loss after May 2.","Gross profit margin improved to 64% from 62%."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009273","json":"https://secwatch.observer/filing/0001641172-25-009273.json","markdown":"https://secwatch.observer/filing/0001641172-25-009273.md","text":"https://secwatch.observer/filing/0001641172-25-009273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000164117225009273/0001641172-25-009273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000164117225009273/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T02:58:23.404000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}